Navigation Links
Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
Date:1/24/2011

74; (Epoetin alfa) and ENBREL recalls.  These increases were partially offset by lower excess capacity charges and lower royalties, primarily for ENBREL.Research & Development (R&D) expenses decreased 5 percent to $825 million in the fourth quarter of 2010 versus $864 million in the fourth quarter of 2009.  This decrease was driven primarily by the $60 million licensing fee payment in the fourth quarter of 2009 associated with the Array BioPharma agreement.  This decrease in licensing fees was partially offset by lower cost recoveries associated with ongoing collaborations and higher staff related costs in 2010.For the year, R&D expenses were $2,773 million in 2010 versus $2,739 million in 2009, an increase of 1 percent.  The increase was driven primarily by lower cost recoveries associated with ongoing collaborations and higher staff related costs in 2010.  This was largely offset by lower licensing fees, principally associated with payments made in 2009 under the Cytokinetics and Array BioPharma agreements, and reduced denosumab clinical trial expenses in 2010.Selling, General & Administrative (SG&A) expenses declined slightly to $1,142 million in the fourth quarter of 2010 versus $1,159 million in the fourth quarter of 2009.For 2010, SG&A expenses increased 5 percent to $3,925 million versus $3,737 million in 2009.  This increase was due primarily to higher staff related costs, higher promotional costs for Prolia and other marketed products, and higher litigation expenses.ENBREL profit share expenses were $319 million and $1,184 million and $308 million and $1,163 million for the three and twelve months ended Dec. 31, 2010 and 2009, respectively.The adjusted tax rate for the fourth quarter of 2010 was 15.5 percent compared to 15.9 percent for the fourth quarter of 2009.  The decrease was due primarily to the full year benefit of the federal R&D credit recognized in the fourth quarter of
'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. PLC Systems Reports Fourth Quarter 2007 Results
5. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
8. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
9. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Echo Therapeutics, ... device company focused on skin permeation, continuous glucose ... Scott W. Hollander has been appointed Chief ... has more than 20 years of experience in ... and most recently served as Vice President, Business ...
(Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... patent infringement action against Chinese medical device manufacturer BMC Medical ... ruled today that BMC,s masks listed below infringe ResMed,s patents, ... selling these masks in the United States ... N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... 11, 2011 Amarin Corporation plc (Nasdaq: AMRN ... on cardiovascular disease, today announced that it has completed its ... at a price to the public of $7.60 per ADS. ... underwriters, over-allotment option, the company sold a total of 13,800,000 ...
... CITY, Mo., Jan. 11, 2011 Clients ... Health Solutions, LLC, now have access to a customizable, ... drug claims. Medical Drug Management Service™ (MDMS) is a ... trend management, assist with appropriate and consistent patient care ...
Cached Medicine Technology:Amarin Announces Successful Completion of Offering of American Depositary Shares 2Amarin Announces Successful Completion of Offering of American Depositary Shares 3DST HealthCare Launches Medical Drug Management Service™ 2DST HealthCare Launches Medical Drug Management Service™ 3
(Date:12/25/2014)... SmileStix ” was featured on NewsWatch as part of its ... on the iOS, Android, and Windows markets. Andrew Tropeano, a ... review and shared with viewers how this is an application ... goes, “A picture says a thousand words.” It’s true. There ... image, because each picture holds a unique and special meaning. ...
(Date:12/25/2014)... 2014 Parker & Sons, Inc. an ... and affordable quality regarding heating, cooling and plumbing services ... 2014 by the “Queen of Clean” for impressive contractor ... impressive reputation over the years for providing outstanding quality ... of contractor services for both homeowners and businesses. Linda ...
(Date:12/24/2014)... December 24, 2014 Connie Casad, MD, ... functional medicine advocate with 30 years of practice experience ... evaluate the health benefits of dietary detoxification. The second ... participants following excellent results from test patients who just ... to explain her interest in conducting the study, Dr. ...
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
(Date:12/24/2014)... 25, 2014 The report “Stivarga (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is a drug which is used in the treatment ... administered and is also prescribed to patients who suffer ... FDA approved is a multi-kinase inhibitor and it blocks ...
Breaking Medicine News(10 mins):Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... a trend setter of sorts. Now, BT Offices and Vans ... that smoking is banned in the BT premises as well ... Importantly, this move might encourage “anti-smoking” initiatives in other industries ... announcement, which will surely set a precedent. Now this means ...
... revealed that although cardiologists are well informed about the possibility ... consequence of eating vegetarian diet, they fail to recommend patients ... // ,With this on one side, studies ... show that they are more than willing to adapt the ...
... to tackle any Bird Flu cases. A 10-bedded ward has ... and another 20// bedded ward has been set up at ... patients with avian influenza or bird flu., ,Another step ... food restaurant in the city to obtain chickens from only ...
... than famous, is now going to face some competition. Private ... Canada, having garnered enough support from the several provinces in ... the Quebec government, which intended to remove the ban on ... offered to chip in and pick up costs for such ...
... or blame all those people who had been telling you ... part for bone strength but is not the only one.,It ... ,As per a recent study which is part of Woman's ... D supplements may not be effective in preventing osteoporosis in ...
... are thrice as likely to miscarry during the first three ... // The study is the first of it’s kind to ... pregnancy loss at an early stage. ,Cortisol is ... levels of this hormone serve as a reliable stress indicator. ...
Cached Medicine News:Health News:Calcium in isolation no good for maintaining bone integrity 2Health News:Early Miscarriage Common In Women Under Stress 2
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Glucose tubes contain an anti-coagulant and a stabiliser. The tubes are ideal for glucose and lactate determinations....
BD Vacutainer® Fluoride Tubes - Plastic...
VACUETTE Trace Element tubes - Non-ridged (pull cap) are designed to test trace elements such as Cu, Zn, Pb, etc....
Medicine Products: